Dexcom's G6 made glucose monitoring continuous and fingerstick-free

Fingerstick meters give point samples, so the dangerous swings between tests go unseen, especially for people with type 1 diabetes who use injections rather than pumps.

Dexcom's G6 puts a small sensor under the skin that measures interstitial glucose every few minutes and streams trends and alarms. Authorized by the FDA in March 2018 (De Novo DEN170088), it was the first real-time integrated CGM with factory calibration — no fingersticks for calibration or treatment decisions — and a 10-day wear.

The DIAMOND randomized trial (158 adults, JAMA 2017) found CGM lowered HbA1c by 1.0 percent versus 0.4 percent for injection users at 24 weeks, with 93 percent of participants wearing the sensor six days a week or more.

Sell the trend, not the number — and drop the fingersticks

Continuous trend data reveal patterns a snapshot cannot.

Alarms turn dangerous lows into preventable events.

Factory calibration removed the biggest adoption barrier.

Longer wear and smartphone streaming cut the daily burden.

A monitoring tool wins when it removes its own maintenance: every calibration, charge and swap is friction that a point-in-time product never had to carry.

The G6's integrated-CGM designation let it drive automated insulin-dosing systems, and the smaller G7 followed; CGM moved from specialty to standard of care for insulin users.